Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
Milton Packer(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Faı̈ez Zannad(Inserm), Cordula Zeller(Inserm), Inder S. Anand(University of Minnesota), Martina Brueckmann, John R. Teerlink(San Francisco VA Medical Center), Markus Haass(St. Hedwig-Krankenhaus), Javed Butler(University of Mississippi Medical Center), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(University of London), Steen Pehrson(Copenhagen University Hospital), Sven Schnaidt(Inserm), Peter E. Carson(Inserm), Wolfram Doehner, Alan B. Miller(University of Florida), João Pedro Ferreira(Inserm), Stefan D. Anker(German Centre for Cardiovascular Research), Michel Komajda(Institute of Cardiology), Waheed Jamal(Inserm)
Cited by 422
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k